In8bio, Inc. (INAB)
NASDAQ:INAB
Want to see INAB full AI Analyst Report?
INAB Stock Chart & Stats
$1.44
-$0.04(-11.59%)
At close: 4:00 PM EST
$1.44
-$0.04(-11.59%)
Day’s Range― - ―
52-Week Range$1.17 - $4.17
Previous CloseN/A
Volume363.43K
Average Volume (3M)70.47K
Market Cap
$15.16M
Enterprise Value-$10.92M
Total Cash (Recent Filing)$21.94M
Total Debt (Recent Filing)$2.35M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 06, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.76
Shares Outstanding9,847,089
10 Day Avg. Volume91,864
30 Day Avg. Volume70,474
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap-0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.84
Enterprise Value/Ebitda0.64
Forecast
1Y Price Target
$5.00Price Target Upside247.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & SafetyRobust repeat-dose glioblastoma data showing materially longer PFS and encouraging OS signals, plus a clean safety profile, strengthen the program's therapeutic rationale. Durable efficacy and tolerability improve prospects for regulatory engagement, investigator adoption, and potential labelable differentiation in an underserved indication.
Conservative LeverageLow and falling debt reduces financial fragility and interest burden, giving management greater flexibility to fund R&D decisions. A conservatively levered balance sheet is a durable strength for a clinical-stage biotech, lowering default risk and preserving optionality for partnerships or milestone-driven financing.
Improving Cash Burn TrajectoryA materially reduced burn rate signals better cost discipline or program prioritization, extending runway per dollar of capital. While still cash-negative, sustained improvement increases the likelihood management can reach key clinical or regulatory inflection points before needing material additional funding.
Bears Say
No Revenue & Persistent LossesAs a pre-revenue developer, IN8bio lacks operating cash generation and depends on milestones or financing to sustain R&D. Persistent multi-year losses mean the company must secure external capital to continue operations, making clinical progress and funding access determinative of long-term viability.
Reliance On Equity FinancingEstablishing an at-the-market equity program is a structural indicator of ongoing dependence on equity issuance to fund operations. This creates dilution risk and ties funding capacity to market conditions, which can constrain strategic choices and increase long-term shareholder dilution if clinical progress is slower than expected.
Eroding Shareholders' EquityA shrinking equity base reflects cumulative negative earnings and reduces financial cushions against adverse outcomes. Lower book equity limits borrowing capacity and heightens sensitivity to future financing needs, making the company more reliant on dilutive capital or strategic partnerships to fund development.
IN8bio News
INAB FAQ
What was In8bio, Inc.’s price range in the past 12 months?
In8bio, Inc. lowest stock price was $1.17 and its highest was $4.17 in the past 12 months.
What is In8bio, Inc.’s market cap?
In8bio, Inc.’s market cap is $15.16M.
When is In8bio, Inc.’s upcoming earnings report date?
In8bio, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were In8bio, Inc.’s earnings last quarter?
In8bio, Inc. released its earnings results on May 07, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.618 by $0.358.
Is In8bio, Inc. overvalued?
According to Wall Street analysts In8bio, Inc.’s price is currently Undervalued.
Does In8bio, Inc. pay dividends?
In8bio, Inc. does not currently pay dividends.
What is In8bio, Inc.’s EPS estimate?
In8bio, Inc.’s EPS estimate is -0.34.
How many shares outstanding does In8bio, Inc. have?
In8bio, Inc. has 9,847,089 shares outstanding.
What happened to In8bio, Inc.’s price movement after its last earnings report?
In8bio, Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.618. Following the earnings report the stock price went down -1.25%.
Which hedge fund is a major shareholder of In8bio, Inc.?
Currently, no hedge funds are holding shares in INAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
In8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
INAB Stock 12 Month Forecast
Average Price Target
$5.00
▲(247.22% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
VYNE Therapeutics
―
Aprea Therapeutics
―
Ownership Overview
5.04% Insiders
4.50% Mutual Funds
25.63% Other Institutional Investors
63.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---